Quick Answer
Fulcrum Therapeutics, Inc. reported Stockholders Equity of $349.00 million for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +43.6% in Stockholders Equity from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$39.77 million | Q2 2018: -$47.15 million | Q3 2018: -$55.58 million | Q1 2019: -$99.69 million | Q2 2019: -$111.68 million | Q3 2019: $102.13 million | Q1 2020: $70.63 million | Q2 2020: $122.13 million | Q3 2020: $104.99 million | Q1 2021: $127.75 million | Q2 2021: $110.89 million | Q3 2021: $230.61 million | Q1 2022: $189.16 million | Q2 2022: $160.76 million | Q3 2022: $221.41 million | Q1 2023: $296.26 million | Q2 2023: $275.43 million | Q3 2023: $255.46 million | Q1 2024: $213.59 million | Q2 2024: $273.79 million | Q3 2024: $257.29 million | Q1 2025: $228.49 million | Q2 2025: $214.38 million | Q3 2025: $198.37 million.
- Over the full 9 years of available data (2017 to 2025), Fulcrum Therapeutics, Inc.'s Stockholders Equity has grown by 1,149.2%.
- Historical annual values: Fiscal year 2025: $349.00 million | Fiscal year 2024: $243.03 million | Fiscal year 2023: $235.19 million | Fiscal year 2022: $198.94 million | Fiscal year 2021: $211.54 million | Fiscal year 2020: $95.18 million | Fiscal year 2019: $87.15 million | Fiscal year 2018: -$63.67 million | Fiscal year 2017: -$33.27 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: